Signalling Pathways 2014: Sponsors
ESMO gratefully acknowledges the valuable contribution of the following organisations in the ESMO Symposium on Signalling Pathways 2014 – Targeting the PI3K/AKT/mTOR Pathway in Cancer.
Premium Educational Grants
One Health Plaza
East Hanover, NJ 07936-1080
United States of America
Tel: +1 888 669 6682
Novartis Oncology discovers and develops innovative therapies, including Glivec® (imatinib), Tasigna® (nilotinib), Jakavi®(ruxolitinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide acetate for injectable suspension), Signifor®(pasireotide) and Exjade® (deferasirox). Novartis has one of the broadest and most comprehensive oncology pipelines in the industry.
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, and a leader in oncology. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.